Analyst firms · Raymond James · ARCT

Raymond James ARCT price target and rating history

Arcturus Therapeutics Holdings Inc. (ARCT) · Health Care

Raymond James rates Arcturus Therapeutics Holdings Inc. (ARCT) Underperform, as of its latest action on Aug 10, 2022. It has published 3 rating actions on ARCT since August 2021, including 1 upgrade and 2 downgrades. Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.

Current rating
Underperform
Price target
Not stated
Median target, all firms
$20
Actions on ARCT
3

Every Raymond James rating on ARCT

How other firms rate ARCT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
CitigroupBuy$20Sep 24, 2026
B. Riley SecuritiesBuy$22Mar 18, 2026
Roth CapitalBuy$20Jan 23, 2026

Questions about Raymond James and ARCT

What is Raymond James's rating on ARCT?
Raymond James rates ARCT Underperform, a bearish rating, as of Aug 10, 2022.
When did Raymond James last change its view on ARCT?
On Aug 10, 2022, Raymond James downgrades to Underperform from Mkt Perform.
How does Raymond James's ARCT target compare with other analysts?
Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.

More ARCT rating histories

All Raymond James ratingsARCT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.